Kenneth I. Ataga

Hematology

1325 Eastmoreland Ave Ste 101
Memphis, TN 38104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 124 publications

The CYB5R3 T117S Missense Variant is Associated with Attenuated Riociguat Efficacy in Sickle Cell Disease.

The CYB5R3 T117S Missense Variant is Associated with Attenuated Riociguat Efficacy in Sickle Cell Disease.

Journal: Blood

Published: March 31, 2026

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).

A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).

Journal: American journal of hematology

Published: February 11, 2026

Natural History of Chronic Kidney Disease in Sickle Cell Disease.

Natural History of Chronic Kidney Disease in Sickle Cell Disease.

Journal: American journal of hematology

Published: February 07, 2026

The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia-Associated Kidney Function.

The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia-Associated Kidney Function.

Journal: American journal of hematology

Published: December 29, 2025

Enhanced PIEZO1 function contributes to the pathogenesis of sickle cell disease.

Enhanced PIEZO1 function contributes to the pathogenesis of sickle cell disease.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: October 02, 2025

NO (nitric oxide) to priapism with hydroxyurea and tadalafil.

NO (nitric oxide) to priapism with hydroxyurea and tadalafil.

Journal: Blood

Published: June 26, 2025

Enhanced PIEZO1 Function Contributes to the Pathogenesis of Sickle Cell Disease.

Enhanced PIEZO1 Function Contributes to the Pathogenesis of Sickle Cell Disease.

Journal: bioRxiv : the preprint server for biology

Published: April 01, 2025

Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.

Development of Polygenic Risk Score for Persistent Albuminuria in Children and Adults With Sickle Cell Anemia.

Journal: American journal of hematology

Published: November 02, 2024

Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.

Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial.

Journal: The Lancet. Haematology

Published: September 24, 2024

Comment on: Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel.

Comment on: Managing sickle cell disease and related complications in pregnancy: results of an international Delphi panel.

Journal: BMC pregnancy and childbirth

Published: August 26, 2024

Concerns With Statistical Analysis of 2016 CDC Opioid Guideline and Sickle Cell Outcomes-Reply.

Concerns With Statistical Analysis of 2016 CDC Opioid Guideline and Sickle Cell Outcomes-Reply.

Journal: JAMA internal medicine

Published: July 22, 2024

Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.

Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial.

Journal: The Lancet. Haematology

Published: June 19, 2024

Showing 1-12 of 124

Last Updated: 09/26/2026